SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — Oct 9, 2018
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: Oct. 9, 2018 · CIK: 0000921114 · Accession: 0001144204-18-052986
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226959
Letter
Via EDGAR Division of Corporation Finance File No. 333-226959 Acceleration Request Requested Date: October 10, 2018 Requested Time: 5:00 P.M. Eastern Time
Dear Ms. Yale:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended (File No. 333-226959) (the “Registration Statement”), to become effective on October 10, 2018, at 5:00 P.M. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our legal counsel, Cooley LLP, confirming this request. The Registrant hereby authorizes each of James Pennington and Asa Henin of Cooley LLP, counsel to the Registrant, to make such request on its behalf. The Registrant is aware of its obligations under the Securities Act.
Once the Registration Statement has been declared effective, please orally confirm that event with James Pennington of Cooley LLP, counsel to the Registrant, at (858) 550-6029, or in his absence, Asa Henin of Cooley LLP at (858) 550-6104.
Very truly yours,
AmpliPhi Biosciences Corporation
Show Raw Text
CORRESP
1
filename1.htm
3579 Valley Centre Drive, Suite 100
San Diego, CA 92130
Via EDGAR
October 9, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Dorrie Yale
Re: AmpliPhi Biosciences Corporation
Registration Statement on Form S-1
Filed August 21, 2018, as amended
File No. 333-226959
Acceleration Request
Requested Date:
October 10, 2018
Requested Time:
5:00 P.M. Eastern Time
Dear Ms. Yale:
In accordance with
Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned registrant
(the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-1, as amended (File No. 333-226959) (the
“Registration Statement”), to become effective on October 10, 2018, at 5:00 P.M. Eastern Time, or as
soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call
to the staff. This request for acceleration is subject, however, to your receiving a telephone call prior to such time from our
legal counsel, Cooley LLP, confirming this request. The Registrant hereby authorizes each of James Pennington and Asa Henin of
Cooley LLP, counsel to the Registrant, to make such request on its behalf. The Registrant is aware of its obligations under
the Securities Act.
Once the Registration
Statement has been declared effective, please orally confirm that event with James Pennington of Cooley LLP, counsel to the Registrant,
at (858) 550-6029, or in his absence, Asa Henin of Cooley LLP at (858) 550-6104.
Very truly yours,
AmpliPhi Biosciences Corporation
By:
/s/ Steve R. Martin
Steve R. Martin
Chief Financial Officer
cc: Paul C. Grint, M.D., AmpliPhi Biosciences Corporation
Thomas A. Coll, Esq., Cooley LLP
Rick A. Werner, Esq., Haynes and
Boone, LLP